@xconomy.com 6 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 1 year ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com 1 year ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com 1 year ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug